These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 15040534)

  • 21. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
    Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
    AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].
    Pinto JL; López Lavid C; Badia X; Coma A; Benavides A
    Med Clin (Barc); 2000; 114 Suppl 3():62-7. PubMed ID: 10994566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.
    Hubben GA; Bishai D; Pechlivanoglou P; Cattelan AM; Grisetti R; Facchin C; Compostella FA; Bos JM; Postma MJ; Tramarin A
    AIDS Care; 2008 Apr; 20(4):449-55. PubMed ID: 18449822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
    AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
    Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
    Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
    Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
    Mauskopf J; Brogan AJ; Talbird SE; Martin S
    AIDS; 2012 Jan; 26(3):355-64. PubMed ID: 22089378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
    Mocroft A; Ledergerber B; Viard JP; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen AB; Phillips AN; Lundgren JD;
    J Infect Dis; 2004 Dec; 190(11):1947-56. PubMed ID: 15529259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
    De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ;
    Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.